Skip to main content
AVACTA GROUP PLC logo

AVACTA GROUP PLC — Investor Relations & Filings

Ticker · AVCT ISIN · GB00BYYW9G87 LEI · 2138009U3EG31OPMGH36 IL Manufacturing
Open in API
Filings indexed 708 across all filing types
Latest filing 2025-03-26 Regulatory Filings
Country GB United Kingdom
Listing IL AVCT

About AVACTA GROUP PLC

https://avacta.com/

Avacta Group PLC is a clinical-stage biotechnology company developing targeted oncology drugs. The company's core technology is the proprietary pre|CISION® platform, a drug delivery system designed to improve the safety and efficacy of potent cancer therapies. The platform works by linking a peptide to a cancer drug, rendering it inactive in the bloodstream. The drug is precisely activated only within the tumor microenvironment by the Fibroblast Activation Protein (FAP) enzyme, which is abundant in many solid tumors. This approach aims to concentrate the active therapy at the tumor site, thereby reducing systemic toxicity and improving the therapeutic window for patients. The company is advancing a pipeline of peptide drug conjugates (PDCs) based on this platform.

Recent filings

Filing Released Lang Actions
Avacta Announces Presentations at AACR
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated March 26, 2025. The title is 'Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting'. The content details specific abstract numbers, session categories, and dates for poster presentations at a scientific conference (AACR Annual Meeting). This is an announcement about future events and data dissemination, not the full financial report (10-K, IR) or a general regulatory filing (RNS). Since it is an announcement detailing specific corporate/scientific updates intended for investors and the public, and it is not a standard financial report, management change, or dividend notice, it fits best under the general 'Regulatory Filings' category (RNS) as a specific corporate news release, or potentially an Investor Presentation (IP) if it were the presentation itself. However, since it is an *announcement* of presentations, and it carries the RNS header, RNS is the most appropriate general classification for this type of market communication that doesn't fit a more specific category like ER or DIV. Given the options, RNS serves as the best fit for a general, non-financial-specific regulatory news service release.
2025-03-26 English
Avacta Completes Launch Diagnostics Sale
M&A Activity Classification · 99% confidence The document begins with 'RNS Number : 9659B' and contains standard boilerplate language indicating it is distributed via RNS, the news service of the London Stock Exchange, which is approved by the FCA as a Primary Information Provider. The content announces the completion of a specific corporate transaction (sale of a subsidiary) following a previous announcement. This structure—a brief, formal announcement of a material event distributed through an official regulatory news service—is characteristic of a general regulatory filing or news release. Since the definitions do not have a specific code for 'Corporate Transaction Announcement' or 'Material Event Disclosure,' and it is clearly a regulatory news service release, the most appropriate classification is Regulatory Filings (RNS). It is not a full report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a formal announcement distributed via RNS.
2025-03-25 English
Avacta to Present at Leerink Healthcare Conference
Report Publication Announcement Classification · 99% confidence The document is a short announcement (4305 characters) released via RNS (RNS Number: 8864Z) on March 10, 2025. The content explicitly states that 'Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference' and provides details about the presentation time and location, including a link to a live webcast. This structure—a brief announcement about an upcoming event or the publication of information, rather than the full report or transcript itself—fits the definition of a Report Publication Announcement (RPA) or, given the RNS header and general nature, a Regulatory Filing (RNS). Since it is specifically announcing an event/presentation availability, RPA is a strong candidate, but RNS is the most general regulatory announcement category provided for non-standard filings. Given the explicit RNS header and the nature of the announcement (a corporate update/event notice), RNS is the most appropriate general classification, although RPA is also plausible if the focus is strictly on the announcement of information availability. I will select RNS as the primary regulatory filing category for this type of market update.
2025-03-10 English
Avacta announces data update for AVA6000
Earnings Release Classification · 99% confidence The document begins with 'RNS Number : 8110Z' and is dated '07 March 2025'. It contains an announcement from 'Avacta Group PLC' regarding clinical trial data ('AVA6000 in the Phase 1a Dose Escalation'). The text concludes with standard boilerplate language referencing 'RNS, the news service of the London Stock Exchange' and the FCA. This structure is characteristic of a regulatory news service announcement, which is a general disclosure mechanism for listed companies. Since the content is a specific operational update (clinical trial results) and not a formal statutory report (like 10-K or IR), and it is clearly distributed via RNS, the most appropriate classification is the general regulatory filing category, RNS, as it is a regulatory announcement that doesn't fit the more specific categories like ER (Earnings Release) or LTR (Legal Proceedings Report). The document length (8960 chars) is substantial enough to be the announcement itself, not just a pointer to a report. Q1 2025
2025-03-07 English
Avacta to sell Launch Diagnostics
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 8027Z' and is dated '07 March 2025'. It explicitly states it contains 'INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014' and is published via a Regulatory Information Service (RNS). The content details a significant corporate action (sale of a subsidiary, Launch Diagnostics) and provides a corporate update on R&D pipeline progress (AVA6000, AVA6103) and strategic options (NASDAQ dual listing). This structure—a formal announcement of material, non-public information released through an official channel like RNS—is characteristic of a general regulatory announcement. Since it is not a full annual report (10-K), a specific financial release (ER), or a proxy statement, the most appropriate classification is the general regulatory filing category, RNS, as it serves as the primary vehicle for such disclosures on the LSE.
2025-03-07 English
Appointment of Joint Broker
Board/Management Information Classification · 99% confidence The document begins with 'RNS Number : 7481V' and contains information typical of a regulatory news service announcement from the London Stock Exchange (LSE). The content announces the 'Appointment of Joint Broker' for Avacta Group PLC. This type of announcement, which details a change in corporate advisory/brokerage relationships, is a standard regulatory disclosure. Since it is a specific corporate event announcement distributed via RNS, and it doesn't fit into the more specific categories like Director's Dealing (DIRS), Major Shareholding (MRQ), or Dividend (DIV), the most appropriate general category for a miscellaneous regulatory announcement distributed via RNS is 'Regulatory Filings' (RNS). The document length is short (3746 chars), suggesting it is an announcement rather than a full report.
2025-02-04 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.